The first edition of PeptideWorld, Pep IQ's monthly news digest. Four weeks of peptide regulatory updates, late-stage trial readouts, pipeline movement, community protocol shifts, and safety signals — organised, sourced where available, and written without the hype. Scan the headlines below, then expand into each section for the detail.
Headlines at a glance
-
Regulatory
FDA removed 12 peptides from Category 2 on 15 April — but the July PCAC vote will decide actual accessThe RFK announcement landed in February. The FDA acted in April. The peptides are now in a deliberate grey area until the 23–24 July Pharmacy Compounding Advisory Committee meeting decides on 503A bulks list inclusion. Plus: GHK-Cu moves the other way.
-
Trial readouts
Retatrutide TRIUMPH-1 — 28.3% weight loss at 80 weeks, biggest Phase 3 obesity readout to dateLilly's 21 May topline puts retatrutide ~5.8 percentage points ahead of tirzepatide and ~13.4 ahead of semaglutide. Dysesthesia at 12 mg is the safety signal to watch. Seven more TRIUMPH readouts scheduled through 2026.
-
Pipeline movement
Four major pipeline events in four weeks — Foundayo (orforglipron) approved, SYNCHRONIZE-1 hit, MBX Obesity DayOral GLP-1 cleared FDA 1 April. Survodutide Phase 3 obesity met endpoints 28 April. MBX nominated amycretin prodrug MBX 5765 on 11 May. Mazdutide stays China-only. Competition is shifting to route and convenience.
-
Community
Compounding pharmacy access begins to open — and the named-stack vocabulary holds steadyWolverine, Klow, Glow — the protocols clinics know are unchanged. What's changing is supply: pharmacies preparing for July PCAC, research-vendor shutdowns, and oral GLP-1 reshaping the adherence conversation.
-
UK regulatory
UK MHRA position formally unchanged — enforcement-of-marketing quietly tighteningNo new UK legislation in April–May. POMs unchanged, HGH 191AA stays Class C. US reclassification has zero UK effect. But MHRA enforcement of mis-marketed "research peptides" is increasing, and payment-processor friction is the bigger operational issue for UK clinics.
-
Safety
GLP-1 enforcement intensifies even as research-peptide reclassification went the other way80+ warning letters in 12 months. Gram Peptides letter 31 March for retatrutide sales. Peptide Sciences voluntarily shut down. Compounded semaglutide shipments down 90% YoY. 503B Bulks List comment period closes 29 June.
The reclassification finally moved — but not where most people think
The story most of the peptide community has been tracking since HHS Secretary Robert F. Kennedy Jr.'s 27 February 2026 appearance on the Joe Rogan Experience (Episode #2461) — where he signalled that 14 of 19 previously restricted peptides would return to Category 1 — finally produced formal FDA action in April. The reality is more nuanced than the podcast framing suggested.
On 15 April 2026, the FDA published a notice announcing the formal removal of 12 peptide bulk drug substances from Category 2 ("Bulk Drug Substances that Raise Significant Safety Concerns") within seven calendar days. Removal was complete by approximately 22 April. Crucially, the same notice scheduled a Pharmacy Compounding Advisory Committee (PCAC) meeting for 23–24 July 2026 to consider whether these peptides should be added to the 503A bulks list — the formal mechanism by which 503A compounding pharmacies gain explicit authorisation to prepare them.
This leaves the named peptides in a deliberate regulatory grey area: no longer on Category 2, but not yet on Category 1. Compounders cannot rely on the removal alone — they remain dependent on either explicit FDA enforcement discretion or a positive PCAC vote in July. The 2024 PCAC reviews voted against inclusion of all previously reviewed peptides, citing unacceptable safety risk profiles. Whether the political environment of 2026 produces a different outcome remains to be seen.
A separate, often-overlooked item from the same 15 April notice: GHK-Cu is being removed from Category 1 following withdrawal of its nomination — movement in the opposite direction to the headline reclassification. PCAC consultation on GHK-Cu is scheduled before the end of February 2027.
For UK readers, none of this alters UK regulatory status: see Section 05.
- 23–24 July 2026 PCAC meeting — the vote that determines actual 503A access
- Whether FDA exercises informal enforcement discretion during the gap (April → July)
- The five peptides on the original RFK list of 14 that weren't in the formal FDA 12 — clarification expected through the PCAC process
- Any rule-making distinction between 503A (patient-specific compounding) and 503B (outsourcing facility) pathways for the reclassified compounds
Retatrutide TRIUMPH-1 — the biggest Phase 3 obesity readout to date
On 21 May 2026 — four days before this digest publishes — Eli Lilly announced positive topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial for retatrutide. The dataset is the largest weight-loss signal yet published in a Phase 3 obesity trial.
In 2,339 adults with obesity or overweight plus at least one weight-related comorbidity, without diabetes, the 12 mg dose produced an average 28.3% body-weight loss at 80 weeks — equivalent to 70.3 lbs from a 248.5 lb baseline. A pre-specified blinded extension in participants with starting BMI ≥35 continued the curve: 30.3% (85.0 lbs) at 104 weeks. The 4 mg dose, reached with a single escalation step, achieved 19.0% weight loss with a discontinuation rate below placebo. 65.3% of participants on 12 mg fell below the BMI 30 obesity threshold by week 80; 45.3% achieved ≥30% body-weight loss.
For context: this puts retatrutide approximately 5.8 percentage points ahead of tirzepatide's SURMOUNT-1 result and 13.4 points ahead of semaglutide's STEP-1 at comparable timepoints. Dysesthesia was reported in up to 20.9% of 12 mg participants, generally mild and rarely leading to discontinuation. Gastrointestinal side effects followed the typical incretin pattern. No unexpected safety signals on pancreatitis, thyroid or severe hypoglycaemia in the non-diabetic population.
TRIUMPH-1 is one of eight pivotal trials in the TRIUMPH program plus a separate ~10,000-patient cardiovascular outcomes study. TRIUMPH-4 (obesity + knee osteoarthritis) already reported in December 2025 with 28.7% weight loss at 68 weeks plus a 75.8% reduction in WOMAC pain scores. Seven additional Phase 3 readouts are scheduled through the rest of 2026, including TRIUMPH-2 (T2D) and TRIUMPH-3 (established cardiovascular disease) expected in Q2–Q3 2026. Detailed TRIUMPH-1 results are expected at the American Diabetes Association's 86th Scientific Sessions in June.
- TRIUMPH-2 (T2D) and TRIUMPH-3 (established CVD) readouts later in 2026
- Cardiovascular outcomes data — whether the triple-agonist mechanism delivers beyond GLP-1 monotherapy
- The dysesthesia signal as patient numbers scale toward real-world use
- NDA submission and timeline — TRIUMPH-1 is the trial designed to anchor the obesity weight-management filing
Four major events in four weeks — orforglipron approval, SYNCHRONIZE-1, MBX Obesity Day, mazdutide China
The pipeline window for this digest contained an unusually dense cluster of named events.
1 April 2026 — Foundayo (orforglipron) FDA approval. Lilly's once-daily oral GLP-1 received approval for obesity and overweight-with-comorbidity. 12.4% average weight loss at the highest dose in Phase 3 trials. Approved without food or water timing restrictions — the only oral GLP-1 to carry that label. Pricing starts at $149/mo self-pay, $25/mo with commercial insurance. Notably, this was the first new molecular entity approval under the FDA's Commissioner's National Priority Voucher (CNPV) pilot program — issued 50 days post-filing, the fastest NME approval since 2002. Submitted in 40+ countries.
28 April 2026 — Survodutide SYNCHRONIZE-1 Phase 3 topline. Boehringer Ingelheim's GLP-1/glucagon dual agonist met co-primary endpoints in non-diabetic obesity/overweight: 16.6% average weight loss at 76 weeks vs 3.2% placebo. Full data is scheduled for the ADA 2026 Scientific Sessions in June. Survodutide also holds FDA Breakthrough Therapy designation for non-cirrhotic MASH with moderate or advanced fibrosis, with two further Phase 3 trials (LIVERAGE and LIVERAGE-Cirrhosis) ongoing in liver disease. FDA filing for obesity is expected to follow further SYNCHRONIZE program readouts in 2026.
11 May 2026 — MBX Biosciences "Obesity Day". MBX presented initial blinded Phase 1 data on MBX 4291, a GLP-1/GIP co-agonist prodrug designed for once-monthly dosing: 7% mean weight loss at 8 weeks with dose-proportional exposure, ~26-day T½, and limited GI events. Same day, MBX nominated MBX 5765 as its amycretin prodrug development candidate — a novel GLP-1/GIP/glucagon/DACRA agonist for once-monthly dosing. A separate GLP-1/GIP/glucagon triple-agonist candidate nomination is expected in Q3 2026.
Mazdutide (Innovent). Already approved by China's NMPA for chronic weight management (June 2025, based on GLORY-1) and for glycemic control in adults with T2D (September 2025). The world's first dual GCG/GLP-1 receptor agonist approved anywhere. Innovent has run seven Phase 3 studies in China including GLORY-1/2/3 (obesity) and DREAMS-1/2/3 (T2D). A supplementary application for a 9 mg dose targeting moderate-to-severe obesity was accepted for NMPA review in November 2025. Not yet submitted to FDA or EMA as of April 2026 — global status remains China-only. Pep IQ has moved Mazdutide into the new Frontier (Coming Soon) section to track external-market progression.
The unifying observation: pipeline competition is consolidating around dose convenience, route, and tolerability rather than weight-loss magnitude alone. Oral and once-monthly formulations are where the next differentiation is being staged.
- Boehringer's BI 3034701 — first-in-class GLP-1/GIP/NPY2 triple agonist, entering Phase II
- MBX triple-agonist candidate nomination Q3 2026
- Mazdutide US/EU regulatory pathway — whether Lilly or Innovent moves first
- SYNCHRONIZE-2 (with T2D) and SYNCHRONIZE-CVOT readouts later in 2026
- LIVERAGE (survodutide MASH) Phase 3 data — competitive context against resmetirom
Pharmacy access starts to open — and the community's stack vocabulary holds steady
The two visible patterns in clinic and community conversation across the four-week window are supply-side movement and stack-naming stability.
On the supply side: the FDA's April 15 removal of 12 peptides from Category 2 (Section 01) has begun to translate into compounding-pharmacy interest, though most pharmacies are pausing until the July PCAC outcome before resuming production at scale. Some 503A facilities are preparing to compound — sourcing FDA-registered API, validating processes, completing documentation — but few are yet dispensing the previously-restricted peptides. The practical effect: research-vendor sourcing remains dominant for the named-and-now-unrestricted compounds, with pharmacy access expected to phase in through Q3 2026 if PCAC votes favourably.
Stack vocabulary in community discussion has stayed remarkably stable. The dominant named protocols are the same ones the audience already knows: Wolverine Stack (BPC-157 + TB-500) for tissue and tendon repair; Klow Blend (BPC-157 + TB-500 + GHK-Cu + KPV) and Glow Blend (BPC-157 + TB-500 + GHK-Cu) for skin and recovery use; growth-axis stacks pairing a GHRH analogue with a GHRP (e.g., CJC-1295 + Ipamorelin). What's changed is the routes-to-acquire — not the protocols themselves.
Within the wider GLP-1 conversation: oral orforglipron (Foundayo)'s 1 April FDA approval has begun shifting the discussion around adherence patterns. The combination of a once-daily oral GLP-1 without food/water restrictions and meaningful weight loss (12.4% at the highest dose) has clinics revisiting whether patient drop-off from injectable adherence problems was as much a behavioural-design issue as a tolerability issue.
Where the conversation is moving away from: speculative microdose-stacking protocols without clear endpoint targets, and stacks built around compounds without translational human data — particularly as pharmacy supply opens up for the better-evidenced compounds and the cost of "real" sourcing falls relative to research-grade.
- How quickly compounding-pharmacy pricing stabilises after PCAC — initial pricing is expected above research-grade levels
- Adherence/retention patterns for orforglipron vs injectable GLP-1s in real-world clinic data
- Whether the established named stacks (Wolverine / Klow / Glow) migrate from research-vendor blends to pharmacy-compounded multi-component formulations
- The "research vendor vs compounded pharmacy" supply distinction as it becomes a meaningful divide in clinic policy
UK MHRA position — formally unchanged, enforcement quietly tightening
The headline for UK practitioners and clinicians is that no UK-specific peptide legislation was announced in April or May 2026. The MHRA framework remains as documented in Pep IQ's UK status strip: GREEN compounds (research-only, legal to possess) stay GREEN; AMBER Prescription-Only Medicines — Semaglutide (Wegovy/Ozempic), Tirzepatide (Mounjaro), Liraglutide, SS-31, Bremelanotide, Oxytocin, Tesamorelin — remain POM; HGH 191AA stays the only RED (Class C controlled) entry.
The substantive shift is on the enforcement-of-marketing side. Independent industry briefings indicate the MHRA is increasing enforcement against websites and operators marketing research peptides as suitable for human use — that is, the line between lawful "research-use-only" supply and consumer-facing health claims. Labelling, COA publication, and accurate research-use disclaimers have become materially more important than they were 12 months ago. Pep IQ's editorial position remains unchanged: document what is being researched, surface what is being used in practice, do not facilitate commercial supply, do not make medical claims.
The US FDA reclassification (Section 01) has no direct effect on UK regulatory status. UK status is set independently by MHRA under the Human Medicines Regulations 2012 and the Misuse of Drugs Act 1971 framework — the FDA's 503A bulks list is a US compounding framework with no UK analogue. The newly-approved Foundayo (orforglipron) in the US has not yet been submitted to the MHRA at the time of writing, though Lilly has stated a target of 40+ country submissions following US approval.
Macro context worth knowing for UK clinic operations: payment processors and merchant-services providers have continued tightening restrictions on "high-risk" wellness/medical services including peptide therapy through Q1 2026 — a commercial friction that affects UK-based clinic operations more often than direct MHRA action does.
- Any MHRA guidance specifically on research-peptide marketing and supply standards (rumoured to be in scope but not announced)
- Whether Foundayo (orforglipron) MHRA submission appears on the regulator's published assessment timetable
- NICE position-statement updates on Wegovy/Mounjaro eligibility — affects clinic referral routes
- Any Home Office consultations touching peptide scheduling (none currently announced)
GLP-1 enforcement intensifies — even as the reclassification headline went the other way
The story most peptide-community readers missed: even while the FDA was preparing the formal Category 2 → 1 reversal for the 12 named research peptides (Section 01), it has simultaneously been escalating enforcement against compounded and unapproved GLP-1 supply. The two tracks are separate and the signal is unambiguous: liberalisation for research peptides with no approved drug analogue; tightening for compounds that are approved as branded drugs.
By the headline numbers: more than 80 warning letters issued in the 12 months ending March 2026 to telehealth companies and online sellers of compounded GLP-1 products — semaglutide, tirzepatide, and increasingly retatrutide as it approaches NDA. 30 warning letters were issued to telehealth companies in early March 2026 alone. Compounded semaglutide shipments are down approximately 90% year-on-year; tirzepatide down 34%.
Specific April-May actions worth knowing: Gram Peptides received a Warning Letter dated 31 March 2026 from CDER concerning sales of "Retatrutide" via its website during a January–March FDA review. In early March 2026, research-peptide vendor Peptide Sciences voluntarily shut down and pulled its product catalog offline — a significant supply-side event for the community that has gone largely uncommented in clinic discussions. On 6 February 2026, the FDA announced it would take steps to restrict the GLP-1 APIs that continue to be used in non-FDA-approved compounded products.
A near-term item of consequence: the FDA's proposed exclusion of semaglutide, tirzepatide, and liraglutide from the 503B Bulks List has a public comment period closing 29 June 2026. Whichever way that decision lands, it will reshape the supply landscape for compounded GLP-1s.
Counterfeit and purity issues remain the persistent community-side concern. The 2018 falsification analysis cited across industry briefings still serves as the cautionary baseline — purity ranges of 5–75% in supposedly research-grade product, with some samples showing lead concentrations 10× safety limits. The 2026 supply churn (vendor shutdowns, new entrants, pharmacy migration) is likely to widen rather than narrow that quality variance in the short term.
- 29 June 2026 — FDA 503B Bulks List public comment period closes for semaglutide/tirzepatide/liraglutide
- Any criminal referrals from the warning-letter wave — multiple law firms have flagged this as the likely next escalation
- Whether FDA enforcement extends from compounded GLP-1s into the research-peptide vendor space
- Independent third-party batch-testing reports as research-vendor consolidation continues
- How clinic policy on COA acceptance shifts as branded compounded supply opens up
About PeptideWorld
PeptideWorld is the rolling monthly news digest for Pep IQ. A new digest publishes every four weeks at its own date-stamped URL. Past digests live in the PeptideWorld Archive for stable reference.
The format is deliberately scannable: bullet-pointed headlines with detail-on-expand, conditional language where evidence is still developing, primary sources cited where available, and explicit "still emerging" markers where the picture isn't yet clear. Pep IQ's editorial stance — rigorous reference, not hype — applies to the digest as much as to the compound entries.